Table 4 Systemic treatment at baseline according to anatomic and clinical classifications of autoimmune uveitis (AU)
From: Autoimmune uveitis: a retrospective analysis of 104 patients from a tertiary reference center
Treatment at baseline | Total number(104 pts) | Anterior autoimmune uveitis(48 pts) | Intermediate autoimmune uveitis(5 pts) | Posterior autoimmune uveitis(45 pts) | Panuveitis(6 pts) | Idiopathic autoimmune uveitis(75 pts) | Systemic disease-associated autoimmune uveitis(29 pts) |
|---|---|---|---|---|---|---|---|
Corticosteroids | 5 (4.8%) | 4 (80%) | 1 (20%) | 0 (0%) | 0 (0%) | 4 (80%) | 1 (20%) |
Corticosteroids + Azathioprine | 36 (34.6%) | 31 (86.1%) | 1 (2.7%) | 4 (11.1%) | 0 (0.0%) | 24 (66.6%) | 12 (33.3%) |
Corticosteroids + Cyclosporine-A | 35 (33.6%) | 9 (25.7%) | 2 (5.7%) | 24 (68.5%) | 0 (0%) | 29 (82.8%) | 6 (17.1%) |
Corticosteroids + Cyclophosphamide | 8 (7.6%) | 0 (0%) | 0 (0%) | 7 (87.5%) | 1 (12.5%) | 6 (75%) | 2 (25%) |
Corticosteroids + Methotrexate | 2 (1.9%) | 1 (50%) | 0 (0%) | 1 (50%) | 0 (0%) | 0 (0%) | 2 (100%) |
Corticosteroids + Combined immunosuppressive therapy | 18 (17.3%) | 3 (16.6%) | 1 (5.5%) | 9 (50%)a | 5 (27.7%) | 12 (66.6%) | 6 (33.3%) |